ELISA/assay

Rat Osteoprotegerin ELISA Kit

MBS721528

48-Strip-Wells-(Competitive)

440 USD

ELISA Kit

Rat Osteoprotegerin ELISA Kit

[Osteoprotegerin]

[osteoprotegerin; Tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily member 11B; osteoprotegerin; osteoclastogenesis inhibitory factor; tumor necrosis factor receptor superfamily, member 11b; Osteoclastogenesis inhibitory factor; Osteoprotegerin]

[OPG]

[TNFRSF11B; TNFRSF11B; OPG; TR1; OCIF; OCIF; OPG]

TR11B_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of OPG. No significant cross-reactivity or interference between OPG and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between OPG and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Cell Culture Supernatants, Body Fluid And Tissue Homogenate. Assay Type: Quantitative Competitive. Sensitivity: 1.0 pg/mL.

Cardiovascular

Intended Uses: This OPG ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Chicken OPG. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: OPG ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-OPG antibody and an OPG-HRP conjugate. The assay sample and buffer are incubated together with OPG-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the OPG concentration since OPG from samples and OPG-HRP conjugate compete for the anti-OPG antibody binding site. Since the number of sites is limited, as more sites are occupied by OPG from the sample, fewer sites are left to bind OPG-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The OPG concentration in each sample is interpolated from this standard curve.

2072185

AAB53709.1

46,026 Da

Apoptosis Modulation And Signaling Pathway (198822); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Monoamine Transport Pathway (198851); Osteoblast Signaling Pathway (198842); Osteoclast Signaling Pathway (198769); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); RANKL/RANK Signaling Pathway (672447)

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal. Protein type: Inhibitor; Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 8q24. Cellular Component: extracellular space; proteinaceous extracellular matrix; extracellular region. Molecular Function: cytokine activity; receptor activity. Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; negative regulation of odontogenesis of dentine-containing teeth; response to estrogen stimulus; apoptosis; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient. Disease: Paget Disease, Juvenile

48-Strip-Wells-(Competitive)

440 USD

48-Strip-Wells-(Sandwich)

440

96-Strip-Wells-(Competitive)

640

96-Strip-Wells-(Sandwich)

640

5x96-Strip-Wells-(Competitive)

2895

5x96-Strip-Wells-(Sandwich)

2895

10x96-Strip-Wells-(Competitive)

5415

10x96-Strip-Wells-(Sandwich)

5415